Diamond, Eli L. http://orcid.org/0000-0001-5456-5961
Francis, Jasmine H.
Lacouture, Mario E.
Rotemberg, Veronica
Yabe, Mariko
Petrova-Drus, Kseniya
Ulaner, Gary A.
Reddy, Ryan http://orcid.org/0000-0001-7501-8676
Abdel-Wahab, Omar
Durham, Benjamin H. http://orcid.org/0000-0001-8090-5448
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R37 CA259260, R01 CA251138, R01 CA242020, P50 CA254838-01, K08 CA218901)
Erdheim-Chester Disease Global Alliance, Frame Family Fund, Applebaum Foundation, Joy Family West Foundation
U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (2KL2-TR-2385)
Melanoma Research Alliance, Prevent Cancer Foundation
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R01 HL128239)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Edward P. Evans Foundation and the Leukemia & Lymphoma Society, Cycle for Survival, and the Marie-Josée and Henry R. Kravis Center for Molecular Oncology
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Fellow Scholar Award in Basic/Translational Research from the American Society of Hematology, Erdheim-Chester Disease Global Alliance
Article History
Received: 7 March 2023
Revised: 2 June 2023
Accepted: 14 June 2023
First Online: 24 June 2023
Competing interests
: OA-W has served as a consultant for H3B Biomedicine, Foundation Medicine Inc, Merck, and Janssen, Loxo Oncology/Lilly and is on the Scientific Advisory Board of Envisagenics Inc and Harmonic Discovery Inc.; OA-W has received prior research funding from H3B Biomedicine, Loxo Oncology/Lilly, Minovia, and Nurix Therapeutics unrelated to the current manuscript. ELD discloses unpaid editorial support from Pfizer Inc and serves on an advisory board for Day One Biotherapeutics, Springworks Therapeutics, and Opna Bio, all outside the submitted work. MEL has a consultant role with Johnson and Johnson, Novocure, Janssen, Novartis, Deciphera, Kintara, RBC/La Roche Posay, Trifecta, Genentech, Loxo, Seattle Genetics, Lutris, OnQuality, Roche, Oncoderm, Apricity and research funding from Lutris, Paxman, Novocure, OQL, Novartis and AZ, all outside the submitte work. MY serves as a consultant for Janssen Research and Development outside the submitted work. VR serves as a medical consultant for Inhabit Brands, Inc outside the submitted work. GAU discloses research grant and paid consultancy and speaker bureau with GE Healthcare and Lantheus, research grant and paid consultancy from Nuclidium, research grants from RazeBio and Curium, and paid consultancy with POINT Biopharma, all outside the submitted work.